1316695-35-8

LM10 (160 mg/kg; p.o.) prevents the growth of TDO-expressing P815 tumor cells and promotes better rejection of control clone P815B cl1, which does not express TDO^[1].
LM10 displays a good TDO inhibition (Ki = 5.6 μM) with a competitive inhibition profile^[1].
LM10 does not inhibit IDO and has a high solubility and bioavailability without obvious signs of toxicity^[1].
The plasma concentration of LM10 after oral administration of 160 mg/kg/day is between 20 and 40 μg/mL (87-175 μM), a concentration about 40 times above the IC₅₀ measured in the cellular assay performed with the physiological concentration of plasma tryptophan^[1].